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Background and Objective: Patients under methadone maintenance therapy (MMT)
are susceptible to several complications including mental disturbances and risk of relapse.
The present study was designed to evaluate the effects of tDCS on relapse, depression,
and anxiety of opioid-dependent patients under methadone maintenance treatment
(MMT).
Methods: It was a randomized-clinical trial that conducted among 27 male patients
referred to the outpatient addiction clinic of Ibn-e-Sina psychiatric hospital in Mashhad
from July 2018 to May 2019. Participants were allocated to two treatment groups
including intervention and sham groups. The intervention group received seven
sessions of tDCS, in the F3 (cathode) and F4 (anode) areas of the brain, each one lasts
20 min, in two consecutive weeks. Depression, anxiety, and stress scale-21 (DASS-21)
were measured before, during, and after the intervention in patients under MMT. Relapse
on the morphine, cannabis, and methamphetamine was screened by urine dipstick tests
of morphine, cannabis, and methamphetamine.
Results: Depression, anxiety, and stress of participants were significantly reduced in the
intervention group compared with the control after the seventh session of tDCS (P <
0.001, P=0.01, and P=0.01, respectively). In addition, the relapse rate showed no
significant changes between the two groups (P=0.33).
Conclusion: Overall, our study demonstrated that depression, anxiety, and stress of
participants were significantly reduced after the seventh session of tDCS, but did not affectin.org April 2020 | Volume 11 | Article 4011
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Frontiers in Pharmacology | www.frontierson the relapse rate. Therefore, it can be applied as a safe and effective technique to relieve
mental disorder among receiving MMT.
Clinical Trial Registration: http://www.irct.ir, identifier IRCT20180604039979N1.Keywords: transcranial direct current stimulation, opioid dependence, relapse, depression, anxiety, stressINTRODUCTION
Addiction is a complex disease that is manifested by compulsive
substance use despite harmful consequences (Bromley, 1992).
Nowadays, a large number of people diagnosed having drug use
disorders and suffered from physical, psychological, cultural,
economic, and social consequences of using substances (Lievens
et al., 2017). The World Health Organization's annual report
estimates that there are about 200 million opiate addicts in the
world (0.6 to 0.8% of the general population), while Iran has nearly
three times higher prevalence compared with the mean prevalence
of the world. Eastern Iran shares a border with Afghanistan where
the majority of opium in the world is produced. Iran is the major
route for drug transport into Europe (Amirabadizadeh et al., 2018;
Soroosh et al., 2019). The most commonly used opioid in Iran is
opium (82%), followed by opium ashes (28%), methadone for non-
medical usages (16.6%), heroin and heroin/cracked (16%), and
morphine (2.6%). Apart from opioids, the common substances that
are illegally used in Iran include alcohol with a prevalence of 2%
within the past 12 months, cannabis with a prevalence of 1%, and
methamphetamine with a prevalence of 0.5%. There are around
5000 outpatient buprenorphine or MMT clinics for the sole
purpose of the treatment of opioid dependency in Iran and
covered about 500,000 people for treatment (Eskandarieh et al.,
2014; Amin-Esmaeili et al., 2016; Ghaderi et al., 2017).
According to the National Institute on Drug Abuse, between
40% and 60% of people recovering from drug addiction will
relapse (Saitz, 2007). The strong desire to re-experience the
effects of the substances after reaching the abstinence, known
as craving, leads to the high relapse rate in patients
(Ahmadpanah et al., 2013). Studies have shown that 20 to 90%
of addicts who receive treatment will relapse in the next 6
months (Sotodeh Asl et al., 2013). Therefore, treatment of the
addiction usually targets the craving in order to decrease the
relapse rate. In some cases, mental disorders such as anxiety,
depression, or schizophrenia precede addiction; in other cases,
drug use disorder may trigger or worsen those mental health
conditions, particularly in people with specific vulnerabilities
(Langas et al., 2011). So, any treatment protocol for drug
addiction usually requires several courses of treatment and
various treatment modalities (Scott et al., 2005).
Transcranial Direct Current Stimulation (tDCS) is one of the
techniques of brain stimulation which involves the use of a weak
direct electric current (e.g., 1 to 2 mA) through two or more
electrodes, usually an anode and a cathode, on the scalp
(Talimkhani et al., 2019). This stimulation acts as a non-
invasive, inexpensive, and safe method for altering the resting
potential of cortical neural cells. Anodal stimulation leads to an
increase of cortical excitability, whereas cathodal stimulationin.org 2reduces cortical excitability. tDCS has few temporary side effects,
including burning sensation and itching under the electrodes,
headache, and fatigue (Fitzgerald et al., 2014; Fertonani et al.,
2015). However, these side effects are reported to be mild and
transient (Brunoni et al., 2014b; Cosmo et al., 2015). According
to brain imaging findings, the dorsolateral prefrontal cortex
(DLPFC) has an essential role in the pathophysiology of drug
craving and emotional distress in patients suffering from
addiction (da Silva et al., 2013). DLPFC has been implicated in
spontaneous and cue-elicited cravings. It is involved in different
cognitive tasks such as decision making, inhibitory control, and
attentional bias, too (Luigjes et al., 2019). Therefore, DLPFC
could be a target for stimulation in order to alleviate the craving
and relapse rate of patients with drug dependence disorder.
However, stimulation of the DLPFC may affect the reward
system via efferent pathways from ventral tegmental area to
the nucleus accumbens (Luigjes et al., 2019). As these pathways
are involve in the hedonic responses of the brain to the
environmental stimuli (Heshmati and Russo, 2015).
Stimulating DLPFC could attenuate negative emotional states
(e.g. depression and anxiety) of patients.
These lines of evidence emphasize the importance of tDCS on
relapse and mental health, suggesting tDCS may have favorable
effects in patients under MMT programs. In addition, it may
potential impact with nursing care, functional activities,
rehabilitation potential, and functional recovery. To our
knowledge, data from studies investigating the effects of tDCS
on promote mental health and relapse in MMT patients are
limited. Therefore, this study was aimed to evaluate the effect of
tDCS on relapse, depression, and anxiety among patients who
underwent MMT.MATERIALS AND METHODS
Trial Design and Participants
This randomized, double-blinded, sham-controlled clinical trial,
registered in the Iranian clinical trials website at (http://www.irct.
ir: IRCT20180604039979N1), followed the Declaration of
Helsinki guideline, informed consent was given by all patients.
This trial was conducted among 27 participants undergoing
MMT, who referred to the Ibn-e-Sina Hospital in Mashhad,
Iran, from July 2018 to May 2019. Twenty-seven patients were
selected through convenient sampling method based on the
criteria. Then, they were divided into the experimental (n=14)
and the sham groups (n=13) (Diagram 1). In term of ethical
considerations, the researchers provided the needed information
to all patients such as process of treatment, probably side effects
of tDCS (such as sense of mild burning or headache) andApril 2020 | Volume 11 | Article 401
Sadeghi Bimorgh et al. tDCS and Relapse, Depression, and Anxietyduration of treatment. Then, they ask patients to write consent
form. All patients received tDCS in 7 sessions (every other day).
The study was approved by the ethics committee of Kashan
University of medical sciences.
Inclusion Criteria
Participants included into the study based on the following
criteria: receiving MMT as the only treatment protocol and for
less than 1 year, evaluated by the drug abuse section of the
Structured Clinical Interview for DSM-IV, aged between 18 andFrontiers in Pharmacology | www.frontiersin.org 360 years, educational attainment of higher or equal to mid-high
school (necessary for completing the questionnaires), not having
diabetes and specific neurological diseases including the history
of head trauma and seizure, not having any metal objects or
prosthesis near the site of brain stimulation, not having cerebral
shunt or cardiac pacemaker.
Exclusion Criteria
The exclusion criteria of the study were the patient's
unwillingness to continue participation, any undesirable sideDIAGRAM 1 | Summary of patient flow diagram.April 2020 | Volume 11 | Article 401
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methadone maintenance treatment.
Randomization and Blinding
Randomization was performed with blanced blocked
randomizaton and random numbers generated by computer
software (Stat Trek software) which choose the random
numbers. Randomization and allocation concealment were
conducted by the researchers and participants and were carried
out by a trained staff at the clinic. Subjects were randomly
allocated into two groups to receive tDCS or sham tDCS. Also,
the participants and researcher were blinded, but the research
assistant was not blinded. Research assistant regulate device on
real or sham mode in the intervention or the sham groups.
Outcomes of Interest
Relapse rate was considered as the primary outcomes of interest.
Depre s s i on and anx i e t y we r e cons ide r ed a s the
secondary outcomes.
Research Instruments
1. Researcher-made background profile form: This form was
used to collect the demographic variables, the daily dosage of
methadone consumed by participants and the duration of
MMT of each participant.
2. Urine dipstick tests for the detection of morphine, cannabis,
and methamphetamine: According to the American Society
for Addiction Medicine (ASAM), drug testing should be used
“to discourage nonmedical drug use and diversion of
controlled substances, to encourage appropriate entry into
addiction treatment, to identify an early relapse, and to
improve outcomes of addiction treatment (Hadland and
Levy, 2016). Urine dipstick drug tests are practical tools for
assessing the relapse in primary care (McDonell et al., 2016).
They are lateral-flow test strips which are analyzed the urine
sample based on the immunochromatography technique. In
the present study, we used Rojan dipsticks (Rojan Azma
Company, Tehran, Iran), which are designed for the
detection of morphine, cannabis, and methamphetamine,
because of the high relapse rate of these substances. Using
dipsticks are very simple, and the results obtained in about 5
min. The results are reported as positive, negative, and invalid
according to the number of color bands appear in the control
and the test region of the strips (Zare et al., 2016). The
Positive result is interpreted as having a relapse, the negative
result is interpreted as to have no relapse, and the invalid
results need to repeat the urine test.
3. Depression, Anxiety, and Stress Scale-21 (DASS-21): The
original version of this scale has 42 questions. However, we
used the short version, called DASS-21. DASS-21 contains 21
items, seven questions measure depression, seven items
measure anxiety, and the rest of them are for measuring
stress. The depression sub-scale measures dysphoria,
devaluation of life, hopelessness, self-deprecation,
anhedonia, lack of interest, and inertia. The anxiety sub-
scale assesses autonomic arousal, situational anxiety, muscleFrontiers in Pharmacology | www.frontiersin.org 4tension, and subjective experience of anxiety; while the stress
sub-scale measures the levels of chronic arousal, difficulty
relaxing and being easily upset, irritable, and impatient. Each
respondent asked to indicate the presence of any symptoms
over the last week. Each question is scaled on the 4-points
Likert scale from 0 to 3. To calculate the final score of DASS-
21, the final score of each sub-scale (depression, anxiety, and
stress) should be multiplied by two (Lovibond, 1995). The
Persian translation of DASS-21 is reported to be valid by
(Sahebi et al., 2005; Babazadeh et al., 2016). Internal
consistency of the DASS-21 subscales with Cronbach's
alphas for depression (0.91), anxiety (0.87), and stress
(0.90) respectively reported (Yazdi et al., 2019). In the
present study, we considered the anxiety and stress sub-
scales as different aspects of anxious affect. So, depression
subscale score of the DASS-21 is interpreted as the level of
depression, while anxiety and stress subscales scores are
interpreted as the level of anxiety of the participants.Research Process
Transcranial Direct Current Stimulation (tDCS) usually involves the
use of a weak and direct electric current (e.g. 1 to 2 mA) through
two or more electrodes which are placed on the scalp (Talimkhani
et al., 2019). The connection of two electrodes with different poles
(usually an anode and a cathode) in different parts of the skull
surface, leads to the stimulation of the lower neurons. Anodal
stimulation induces an increase of cortical excitability, whereas
cathodal stimulation decreases cortical excitability (Brunoni et al.,
2012). Safety of the use of tDCS has been reported in human adults
(Brunoni et al., 2014b; Cosmo et al., 2015).
In the present study, the intervention group received 7
sessions of tDCS, once a day, every other day with the
intensity of 2 mA for 20 min. For anodal stimulation, the
anode electrode was placed over right DLPFC (F4) and for
cathodal stimulation, the cathode electrode was centered over
left DLPFC (F3) based on international 10–20 EEG system
(Batista et al., 2015) (Figure 1). Direct current was transferred
via two electrodes coated in saline-soaked sponges with 35-cm2
size and delivered by a battery-driven stimulator (Oasis Pro,
Mind Alive, Canada). For the sham group, the same methods
were used, and the electrodes were placed in the same areas.
However, the device was turned up to 2 mA for only 30 s to
produce the sense of initial irritation, then slowly ramped-down
to 0 mA over the period of 1 min, and finally turned off, while the
electrodes stayed on the scalp up to 20 min.
In the first session, all participants were asked to fill out
DASS-21 and screened for any relapses on morphine,
amphetamine or cannabis by urinary dipstick before receiving
tDCS or sham. Participants were asked to complete DASS-21
after the fourth the seventh sessions, while the same urinary
screening test was conducted at the end of seventh session, too.
Sample Size
Regarding the relapse rate as the main outcome, no study was
found to calculate sample size. Therefore, this is a pilot study.
Considering the obtained results of relapse rate in this studyApril 2020 | Volume 11 | Article 401
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power was calculated 20% (P-value=0.05). It was obtained 15
patients for each group. However, considering the possibility of
sample loss, we interred 30 participants in the study, but before
randomization, three subjects declined to participation.
Eventually, 27 patients terminated the study (14 in the
intervention group and 13 in the sham group).
Statistical Analysis
The Kolmogorov-Smirnov test was done to determine the
normality of data. We used the Chi-square test, Independent
sample t-test, repeated measures ANOVA, Fisher's exact test,
and Mann-Whitney test to analyze the data, using SPSS-25. P-
values <0.05 were considered statistically significant.RESULTS
In the present study, we evaluated the effects of 7 sessions of
tDCS on the depression, anxiety, stress, and relapse. No side
effects were reported following tDCS sessions in patients under
MMT. So, we did not have any excluded participant after
the randomization.
Mean age, age of first illicit opioids use, marital status,
education, job, and psychiatric comorbidity, use of other drugs,
daily methadone dosage, and duration of MMT were not
significantly different between the intervention and sham
groups (Table 1).
Comparison showed no significant differences about the
relapse rate between the intervention and sham groups (P <
0.999 and P=0.33, respectively) (Table 2). Although noFrontiers in Pharmacology | www.frontiersin.org 5significant differences were found between the two groups in
the mean score of depression, anxiety, and stress before and
during the intervention, at the end of the study, significant
differences were appeared between the two groups in all three
variables (P < 0.001, P=0.01, and P=0.01, respectively).
Compared with the sham group, tDCS resulted in a
significant improvement in depression (P < 0.001), anxiety (P <
0.001) and stress (P < 0.001) in the intervention group (Figures
2–4). The post hoc comparison between the intervention and
sham patients showed a significant group × treatment interaction
on depression (F (2.50) =10.71; p < 0.001), anxiety (F (2.50) 6.48;
P=0.003) and stress (F (2.50) 14.64; P < 0.001). Repeated
measures depression as dependent variables produced a
significant overall F-statistic for interaction effect of time and
group; this finding indicated that the change in the scores on
during the treatment was significantly different in tow groups.DISCUSSION
The findings of the present study indicated that 7 sessions of
tDCS did not conclude the significant differences between the
two groups in relapse. Also, finding showed a significant
difference in depression, anxiety, and stress rate between the
intervention and sham groups at the end of the study. Although
MMT is presented to reduce craving, relapse, and physical
complaints of opiate users after drug discontinuation, some
patients continue to experience serious and severe problems
during the first years of abstinence, including depression,
anxiety, and frequent relapses (Dobson and MOHAMMAD,FIGURE 1 | The anode was placed on the right DLPFC (F4) and cathode
was placed on the left DLPFC (F3) according to the 10–20 international
system for EEG.TABLE 1 | Comparison the background variables between the intervention and
sham groups at the beginning of the study.1
Background Variables Group P
Intervention Sham
Age (y) 37.36 ± 7.63 36.00 ± 5.69 0.69*
Age of first illicit opioids use (y) 21.42 ± 5.8 22.23 ± 4.04 0.68*
Daily methadone dosage (mg) 50.8 ± 17.4 52.0 ± 20.9 0.69*
Duration of MMT (months) 8.93 ± 2.46 8.31 ± 2.78 0.54**
Marital status (%) Single 3 (21.4) 3 (23.1) 0.86***
Married 10 (71.4) 8 (61.5)
Divorced 1 (7.2) 2 (15.4)
Education (%) Intermediate 10 (71.4) 10 (76.9) 0.74***
Diploma 4 (28.6) 3 (23.1)
Job (%) Unemployed 9 (64.3) 4 (30.8) 0.09***
Employed 1 (7.1) 0 (0)
Others 4 (28.6) 9 (69.2)
Psychiatric comorbidity
(%)
None 12 (85.7) 11 (84.6) 0.51***
Mood disorder 1 (7.1) 0 (0)
Others
disorders
1 (7.1) 2 (15.4)
Use of other drugs (%) None 12 (85.7) 12 (92.3) 0.22***
Benzodiazepine 2 (14.3) 0 (0)
Antidepressants 0 (0) 1 (7.7)April 2020 | Volume 11 | Art1Data are mean ± SD for quantitative variables and frequency (%) for qualitative variables.
*Mann-Whitney.
**Obtained from Independent t-test.
***Obtained from Chi-Square.icle 401
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anodal/right cathodal and right anodal/left cathodal to reduce
anxiety and depression (Brunoni et al., 2014a; Taremian et al.,
2019). However, we apply the anode electrode on right DLPFC
(F4) and the cathode electrode on the left DLPFC (F3). All
participants tolerated the procedure and did report no side effects
except for the redness of the stimulation site, which was resolved
after a few minutes.
Effects on Relapse
This study indicated that, compared with the sham groups, tDCS
for 7 sessions in patients with opioid dependence under
methadone maintenance treatment had no significant
differences on the relapse rate. Researchers have performed
different studies on the efficacy of the tDCS on the craving of
patients with substance dependence disorders (Boggio et al., 2008;
Sharifi-Fardshad et al., 2018; Garg et al., 2019; Martinotti et al.,Frontiers in Pharmacology | www.frontiersin.org 62019). Garg et al. reported that the effect size of repeated sessions
of tDCS targeted at prefrontal cortex (left anodal/right cathodal)
on the craving reduction in patients with opioid dependence
disorder was moderate. They could not show any significant
difference in self-reported craving between the intervention and
control groups (Garg et al., 2019). In another study, Taremian
et al. examined the effect of tDCS at the dorsolateral prefrontal
cortex (right anodal/left cathodal) on the craving to opium in a
group of participants with opium use disorder enrolled in MMT
program. The study showed that the active tDCS significantly
reduced craving (Taremian et al., 2019). Martinotti et al. applied
the same protocol (right anodal/left cathodal) on participants
with substance use disorder or gambling disorder in which they
reported a significant reduction of craving in the intervention
group (Martinotti et al., 2019). Sharifi-Fardshad et al. compared
the effects of active tDCS on the DLPFC with the right anodal and
left anodal protocols with the control group and reported that
right anodal active tDCS could reduce the craving in former
heroin users under MMT (Sharifi-Fardshad et al., 2018).
However, Wang et al. examined a different tDCS treatment
protocol on a group of heroin-addicted participants. While they
targeted the bilateral frontal-parietal-temporal circuitry and
placed the cathodes over T3 and T4 and anodes over O2 andFIGURE 2 | Mean depression score and in the intervention and sham groups
at each time point.FIGURE 3 | Mean anxiety score and in the intervention and sham groups at
each time point.FIGURE 4 | Mean stress score in the intervention and sham groups at each
time point.TABLE 2 | Comparison of relapse rate, mean depression, anxiety and stress












Negative 13(92.9) 10(76.9) 0.33*
Positive 1(7.1) 3(23.1)
Depression Before intervention 30. 71 ±
7.75
27.85 ± 8.46 0.37**
During intervention
(after the 4th session)
23.29 ± 7.04 28.31 ± 8.60 0.11**
After intervention 17.57 ± 4.45 25.85 ± 7.09 < 0.001***
Anxiety Before intervention 27.00 ± 8.25 25.38 ± 9.36 0.64**
During intervention 22.29 ± 6.07 25.08 ± 8.31 0.33**
After intervention 16.86 ± 4.20 23.23 ± 7.68 0.01***
Stress Before intervention 33.00 ± 8.07 29.08 ± 8.23 0.14***
During intervention 26.29 ± 7.23 27.69 ± 8.90 0.66**
After intervention 17.28 ± 4.28 25.85 ± 8.38 0.01****Fischer's exact test.
**Independent t-test.
***Mann-Whitney.April 2020 | Volume 11 | Article 401
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were reported after active treatment (Wang et al., 2016).
Although these studies showed promising effects of tDCS in
decreasing the craving of patients with opioid dependence
disorder, they may not be helpful enough in clinical practice.
Assessment of craving in all the above-mentioned studies are
based on self-reports questionnaires or scales. They did not
measure clinical outcomes, and the literature suffered from the
lack of data on the parameters such as relapses (Batista et al.,
2015).We could consider the lapse/relapse as the clinical
consequence of the craving; therefore, assessment of the
relapse rate could be a good indicator of the clinical outcome
of applying the tDCS on the craving.
In our study, applying the right anodal active tDCS, which has
more evidence in reducing craving in different studies, could not
significantly reduce the relapse rate in patients with opioid
dependence disorder enrolled MMT program (Klauss et al.,
2018; Taremian et al., 2019). However, after seventh session of
tDCS, the intervention group had lower relapse rate compared to
the sham group. Lack of significant efficacy of tDCS in our study
could be due to the effect of MMT program on the relapse rate of
participants. MMT could reduce the craving for opioids in
opioid-dependent patients. Therefore, it could interfere with
the efficacy of the tDCS. Other possible reasons of limited
effect of tDCS could be the limited sessions of therapy and the
limited number of participants of the study. All in all, right
anodal/left cathodal protocol of tDCS seems to have little effects
in reducing the relapse rate of patients enrolled MMT programs
in non-laboratory settings.
Effects on Depression and Anxiety
The current study demonstrated that tDCS for 7 sessions among
patients with opioid dependence under methadone maintenance
treatment significantly improved the depression, anxiety, and stress
score compared with the sham subjects. Complaining of depressed
mood is prevalent between patients suffering from opioid
dependence disorder, even after replacing their illegal opioids
with methadone. Half of the patients undergoing methadone
maintenance treatment suffer from depression (Cosmo et al.,
2015). Although depressed feelings after the first weeks of drug
discontinuation could be self-limited, independent depression
needs proper therapeutic management (Nunes and Levin, 2008).
According to cerebral imaging, the dorsolateral prefrontal cortex
(DLPFC) has an important role in the pathophysiology of mood
disorders (Cosmo et al., 2015). Recently, tDCS has been
recommended for treatment of depression with the anode over
the left DLPFC (Bennabi and Haffen, 2018).
According to our study, there was no significant difference
between the intervention and sham groups in the mean score of
depression before and during the treatment. However, after the 7th
session of tDCS, the mean score of depression in the intervention
group was significantly lower than the sham group. While we
applied a different stimulation site (the right DLPFC for anode
electrode instead of the usual recommended stimulation site for
treatment of depression), the significant therapeutic effect of tDCS on
the depression score of participants was an interesting finding.Frontiers in Pharmacology | www.frontiersin.org 7Taremian and his colleagues applied the tDCS in a group of
opioid-dependent individuals with MMT and reported a
significant reduction in the self-reported craving, anxiety, and
depression of the patients (Taremian et al., 2019). It seems that
tDCS could affect the comorbid depression in patients under MMT,
although it is not an early outcome. Comorbid depression in
substance-dependent individuals has different explanations,
including elevated risk of vulnerability for the second disease
caused by the primary disease, common risk factors between
disorders, using substances as self-medication of depression,
residual depression from interpersonal or social consequences of
addiction, delayed recovery caused by the comorbid disorder, and
substance-induced depressive episodes caused by direct biological
changes of addiction (Davis et al., 2008). As depression in opioid-
dependent individuals is not a single disorder with a unique etiology,
we suggest that the right anodal tDCS could have a therapeutic effect
on some types of comorbid depression.
Anxiety is a well-known comorbidity of addiction (Cohn
et al., 2011). While feeling anxious is related to the over-activity
of the noradrenergic system, the core mechanism of action in
opioid withdrawal syndrome is related to the noradrenaline
release in the brain, too (Aston-Jones and Kalivas, 2008).
Therefore, it is usual for opioid-dependent individuals to find
themselves, feeling restless, anxious, and worried. Addressing
anxiety has an important role in the management of addiction.
Anxious mood accompanies different psychological and
somatic symptoms, including autonomic hyperactivity,
restlessness, irritability, muscular twitching, etc. (Association,
2000). The anxiety and the stress sub-scales of DASS-21 assess
these symptoms; therefore, we used these subscales to quantify
anxiety score of participants. We found out that there was no
significant difference between the intervention and sham groups
in the mean scores of anxiety and stress sub-scales before and
during the treatment. However, the intervention group showed a
significant decline in anxiety and stress sub-scales compared to
the sham group after the treatment.
Few studies have reported the effect of tDCS on the anxiety
disorders and fewer in patients with substance dependence
disorders (Hampstead et al., 2016; Kar and Sarkar, 2016). Some
researchers have proposed the placement of cathode electrode on
the right prefrontal cortex and anode electrode on the left
prefrontal cortex (Stein et al., 2020). The hypothesis is that the
cathodal stimulation may reduce cortical excitability in anxiety
disorders, which accompany cortical excitability. Nevertheless, in a
randomized sham-controlled trial of applying tDCS in patients
with cocaine dependence, Batista et al. placed the anode electrode
on the right DLPFC (similar to our study) and reported a
significant decrease in the sense of anxiety in patients receiving
tDCS in comparison to the sham group (Batista et al., 2015). Based
on our findings, applying tDCS could reduce the anxiety symptoms
in patients under MMT, though the outcome is achieved after
seven consecutive sessions. The efficacy of tDCS on the anxiety
symptoms in the Batista et al. and our study may be due to the
overall improvement of the sense of health and well-being of the
patients (Batista et al., 2015). However, more studies should target
anxiety symptoms in patients with substance use disorders.April 2020 | Volume 11 | Article 401
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This study should be viewed in light of its limitations.
Specifically, given it's a pilot study sample size, caution is
advised before generalizing the results. Also, low duration of
intervention that this is associated with illustrate lower effects. In
addition, we were not able to investigate the withdrawal
syndrome, chronic pain, and cognitive functions. Thus, its
performance is suggested in next studies. Also, tDCS is a new
method of brain stimulation. Therefore, most patients especially
women were not familiar with it and refuse to participate in the
study. In addition, the number of participants of the study was
limited. Furthermore, the operator who conducted tDCS was
not blind about the assigned patients (intervention and
sham groups).CONCLUSIONS
The findings suggested the beneficial effect of tDCS to improve
depression, anxiety, and stress in the experimental group compared
to the sham subjects. This suggests that tDCS may confer
advantageous therapeutic potential for patients under MMT
programs. Further research is needed in other participants and for
longer periods to determine the efficacy of tDCS.DATA AVAILABILITY STATEMENT
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